N-(2-cyclohexyl-5-methylpyrazol-3-yl)-2-[5-(2-fluoro-4-pyridinyl)tetrazol-2-yl]acetamide
C18H21FN8O — CID 155555588
Data last refreshed: (MolForge compound catalog, from PubChem)
About N-(2-cyclohexyl-5-methylpyrazol-3-yl)-2-[5-(2-fluoro-4-pyridinyl)tetrazol-2-yl]acetamide
N-(2-cyclohexyl-5-methylpyrazol-3-yl)-2-[5-(2-fluoro-4-pyridinyl)tetrazol-2-yl]acetamide (PubChem CID 155555588) has the molecular formula C18H21FN8O and a molecular weight of 384.42 g/mol. Its IUPAC name is N-(2-cyclohexyl-5-methylpyrazol-3-yl)-2-[5-(2-fluoro-4-pyridinyl)tetrazol-2-yl]acetamide.
Molecular Properties
| Compound Name | N-(2-cyclohexyl-5-methylpyrazol-3-yl)-2-[5-(2-fluoro-4-pyridinyl)tetrazol-2-yl]acetamide |
|---|---|
| PubChem CID | 155555588 |
| Molecular Formula | C18H21FN8O |
| Molecular Weight | 384.42 g/mol |
| Exact Mass | 384.18 |
| IUPAC Name | N-(2-cyclohexyl-5-methylpyrazol-3-yl)-2-[5-(2-fluoro-4-pyridinyl)tetrazol-2-yl]acetamide |
| SMILES | Cc1cc(NC(=O)Cn2nnc(-c3ccnc(F)c3)n2)n(C2CCCCC2)n1 |
| InChI | InChI=1S/C18H21FN8O/c1-12-9-16(27(23-12)14-5-3-2-4-6-14)21-17(28)11-26-24-18(22-25-26)13-7-8-20-15(19)10-13/h7-10,14H,2-6,11H2,1H3,(H,21,28) |
| InChIKey | CIOBUWQLMLGJEN-UHFFFAOYSA-N |
| XLogP | 2.52 |
| TPSA | 103.41 Ų |
| H-Bond Donors | 1 |
| H-Bond Acceptors | 8 |
| Rotatable Bonds | 5 |
| Heavy Atoms | 28 |
| Complexity | — |
Lipinski Rule of Five
Passes Rule of Five
| Rule | Value |
|---|---|
| MW ≤ 500 | 384.42 |
| LogP ≤ 5 | 2.52 |
| H-Bond Donors ≤ 5 | 1 |
| H-Bond Acceptors ≤ 10 | 8 |
Computed Properties (RDKit)
| Structural Alerts | {'alert_name': '2-halo_pyridine', 'substructure': 'N/A'} |
|---|
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 155555588 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.